January 30, 2019
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Read More
January 30, 2019
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Read More
January 30, 2019
Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)
Read More
January 30, 2019
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV
Read More
January 30, 2019
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV
Read More
January 30, 2019
A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection
Read More
January 30, 2019
Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection
Read More
January 30, 2019
Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection
Read More
January 30, 2019
Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
Read More
January 30, 2019
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Read More
January 30, 2019
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Read More
January 30, 2019
Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients
Read More
Load More
X